



**Resonance Health Ltd**  
**ASX / Media Release**

**28 January 2015**

---

## **Managing Director Resignation**

Managing Director, Ms Liza Dunne, has resigned from the Company effective 30th January 2015 to pursue other interests.

Following 11 years with the Company Ms Dunne said "I am delighted to have had the opportunity to be a part of Resonance Health from its early stages soon after listing on the ASX through to the successful international commercialisation of the FerriScan technology and was privileged to lead the Company as Managing Director for the past 6 years. The Company today is in a strong position with significant opportunities ahead - double digit growth in the FerriScan business is expected to continue and a profitable full year result is anticipated for 2014/15. Cash raised in 2014 has provided the funding required to commercialise the HepaFat-Scan product which provides a diagnostic product for the large fatty liver disease market while investment in research and development for an imaging diagnostic tool for liver fibrosis has been accelerated. The time is now right to hand the reins to a new Managing Director and for me to pursue other opportunities."

Commenting on her resignation, Chairman Dr Martin Blake said "It has been my pleasure working with Liza over much of the past 11 years, she has laid a solid foundation for the company and leaves it in the strongest position it has ever been in.

"On behalf of the Board and all the staff, I wish to express our sincere thanks and appreciation to Liza for her service and dedication to the company over many years and her leadership as Managing Director through some difficult years. We wish her all the very best for her future endeavours."

The Board will commence the search for a new Managing Director immediately.

Yours sincerely

Dr Martin Blake  
Chairman  
For further information please contact:

### **Resonance Health**

Adrian Bowers  
Company Secretary  
T: +61 8 9286 5300  
E: [adrianb@resonancehealth.com](mailto:adrianb@resonancehealth.com)

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing imaging core laboratory services for the quantitative analysis of MR medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.